MedTrace Logo

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-01-24

Study results available
· View outcomes & findings →

Summary

This is a single center, prospective, randomized, double blinded placebo controlled study conducted I patients with type 1 diabetes.The aim of this study is to examine the additive effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of possible improved glycemic control, reduced glycemic variability, reduced insulin dosages, additional effects of weight loss and blood pressure reduction.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Dapagliflozin

Dapagliflozin or Farxiga is a SGLT-2 inhibitor

DRUG

Insulin

DRUG

Liraglutide

Victoza(Liraglutide) is a GLP-1 agent.

DRUG

Dapagliflozin placebo

Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin

Sponsors & Collaborators

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Nitesh D Kuhadiya, MD, MPH · University at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2015-12-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02518945 on ClinicalTrials.gov